Celerion
Tempe, Arizona, 85283, United States
NCT Number: NCT03239379
This study is a single-center, randomized, single-blind, placebo (PBO)-controlled, multiple-dose study to characterize the safety, tolerability, PK, and PD of IV BNZ-1 administered to healthy adult subjects once weekly (QW) for 4 doses or once every other week (QOW) for 3 doses. Five cohorts of 6 subjects randomized 5 BNZ-1:1 PBO are planned to be enrolled in the trial. Participants will be followed for 4 weeks after the last dose for safety monitoring, and collection of PK and PD samples.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Tempe, Arizona, 85283, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Injectable peptide antagonist of IL-2, IL-9 and IL-15
Other names: BNZ-1
Normal Saline
Time frame: 8 weeks
general safety evaluation by principal investigator
Time frame: 8 weeks
plasma concentrations collected at multiple times after the first and last doses
Time frame: 8 weeks
plasma concentrations collected at multiple times after the first and last doses
Time frame: 8 weeks
plasma concentrations collected at multiple times after the last dose
Time frame: 8 weeks
Flow cytometry of PBMCs at multiple time points post dose
Time frame: 8 weeks
Flow cytometry of PBMCs at multiple time points post dose
Time frame: 8 weeks
Flow cytometry of PBMCs at multiple time points post dose
Bioniz Therapeutics
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07153900
Safety and Tolerability in Healthy Subjects
Birmingham, Michigan, United States
View Trial DetailsNCT07204171
Chemically-Induced Disorders, Mental Disorders
Overland Park, Kansas, United States
View Trial Details